LB1528C - Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

Friday, October 21, 2022

1:45 PM – 1:55 PM US ET

Location: 209ABC

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Co-Author(s)

Susanna Naggie, MD/MHS

Professor of Medicine with Tenure/Vice Dean of Clinical Research
DCRI/ School of Medicine
Durham, North Carolina, United States

Disclosure: Disclosure(s): AbbVie: Grant/Research Support (); BMS/PRA: Event adjudication (); Gilead Sciences: Grant/Research Support (); Pardes Biosciences: Advisor/Consultant (); Personal Health Insights, Inc: Data Safety Monitoring Board Member (); Silverback Therapeutics: Advisor/Consultant (); Vir Biotechnology: Advisor/Consultant (), Stocks/Bonds ()

Disclosure(s):

Susanna Naggie, MD/MHS: AbbVie: Grant/Research Support (); BMS/PRA: Event adjudication (); Gilead Sciences: Grant/Research Support (); Pardes Biosciences: Advisor/Consultant (); Personal Health Insights, Inc: Data Safety Monitoring Board Member (); Silverback Therapeutics: Advisor/Consultant (); Vir Biotechnology: Advisor/Consultant (), Stocks/Bonds ()